Keyword: Turning Point Therapeutics
Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.
Turning Point pulled in nearly $167 million in its IPO, proceeds earmarked to push its lead asset, repotrectinib, into phase 2 studies.
The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of.
Turning Point’s update on repotrectinib in NSCLC showed more than four-fifths of patients responded to the drug, but its stock fell 10%.